LH vs GRAL vs ADPT Stock Comparison

Labcorp Holdings, Grail and Adaptive Biotechnologies Prices as of Nov 13, 2026 Peers: Industry group
LH Labcorp Holdings Inc.
$370.59 +16.7% 1M +38.3% 1Y
Market cap
$30.24B
P/E
30.1x
Revenue (TTM)
$14.59B
Div. yield
–
Diagnostic Labs Healthcare
5 wins
GRAL GRAIL, Inc.
$115.89 -17.0% 1M +39.3% 1Y
Market cap
$4.98B
P/E
–
Revenue (TTM)
$66.30M
Div. yield
–
Diagnostic Labs Healthcare

Head to Head

7 decided of 12

Labcorp Holdings leads on 5 of the 12 questions below (Labcorp Holdings 5, Adaptive Biotechnologies 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionLHGRALADPTLeader
Larger companyMarket capitalisation $30.24B $4.98B $4.50B LH
Cheaper on earningsLower P/E, profitable companies only 30.1x -12.3x -63.8x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.5x — — –
Faster revenue growthRevenue growth, trailing twelve months +6.0% +12.3% +17.9% ADPT
More profitableNet margin, trailing twelve months 6.9% -255.1% -23.7% LH
Better return on capitalReturn on invested capital 8.3% — — –
Less leveragedLower net debt / EBITDA 2.6x — — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +38.3% +39.3% +105.4% ADPT
Better 5-year returnAnnualised price return, 5 years +7.7%/yr — -2.6%/yr LH
Less volatileAnnualised volatility, 1 year 24.1% 112.9% 67.6% LH
Higher overall scoreMean of the five percentile scores vs peers 57/100 38/100 42/100 LH

Percentile Scorecard

LHGRALADPT

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisLHGRALADPT
Valuation 55 #45 of 99 5 #94 of 99 12 #87 of 99
Growth 36 #57 of 89 42 #52 of 89 83 #16 of 89
Profitability 71 #27 of 92 6 #87 of 92 25 #69 of 92
Financial Health 46 #56 of 103 100 #1 of 103 70 #32 of 103
Shareholder Returns 77 #15 of 63 – 21 #50 of 63
Overall 57 38 42
  • LH ranked among 103 companies in Healthcare Providers
  • GRAL ranked among 103 companies in Healthcare Providers
  • ADPT ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodLHGRALADPTSPY
1 month +16.7%-17.0%+13.3% -2.0%
3 months +16.5%+70.8%+17.4% -2.8%
6 months +48.0%+94.3%+126.3% +2.0%
Year to date +47.7%+35.4%+78.8% +10.6%
1 year +38.3%+39.3%+105.4% +12.2%
3 years +78.1%—+610.0% +68.1%
3 years, per year +21.2%—+92.3% +18.9%
5 years +45.1%—-12.6% +61.4%
5 years, per year +7.7%—-2.6% +10.1%
10 years +245.6%—— +248.5%
10 years, per year +13.2%—— +13.3%

Risk

MeasureLHGRALADPTSPY
Volatility, 1Y 24.1%112.9%67.6% 13.6%
Downside volatility, 1Y 21.5%129.8%62.9% 13.9%
Beta vs S&P 500, 1Y 0.382.901.57 1.00
Return / volatility, 1Y 1.590.351.56 0.90
Max drawdown, 5Y -35.0%-62.9%-92.8% -25.4%
From 52-week high -0.5%-27.1%-4.0% -3.2%
52-week high $372.35$158.92$30.26 $779.14
52-week low $250.39$43.03$12.41 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleLHGRALADPT
P/E now vs peer median 29.9xmedian 22.4x -13.3xmedian 22.4x -66.0xmedian 22.4x
P/S now vs peer median 2.1xmedian 1.3x 32.6xmedian 1.3x 15.7xmedian 1.3x
EV/EBITDA now vs peer median 16.2xmedian 14.2x -9.8xmedian 14.2x -132.7xmedian 14.2x
P/FCF now vs peer median 23.4xmedian 19.0x -16.6xmedian 19.0x -531.8xmedian 19.0x
P/B now vs peer median 3.4xmedian 2.6x 2.1xmedian 2.6x 25.5xmedian 2.6x
PEG now vs peer median 1.72median 0.84 —median 0.84 -1.90median 0.84

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsLHGRALADPT
Revenue $14.59B $66.30M $298.01M
Gross profit $4.23B $75.17M $220.98M
Operating income $1.50B -$578.58M -$48.21M
Net income $1.00B -$406.18M -$70.73M
Free cash flow $1.29B -$312.00M -$8.82M
R&D – $188.17M $83.18M
EPS (diluted) $12.30 $-8.68 $-0.38
Cash & equivalents $261.80M $29.00M $75.62M
Total debt $6.03B – –
Shares (diluted) 81.60M 46.78M 186.88M
Enterprise value $28.33B $1.60B $3.41B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricLHGRALADPT
P/E 29.9x -13.3x -66.0x
P/FCF 23.4x -16.6x -531.8x
P/Operating cash flow 16.6x -16.9x -1,097x
P/S 2.1x 32.6x 15.7x
P/B 3.4x 2.1x 25.5x
P/Tangible book 5.9x 7.3x 25.6x
EV/EBITDA 16.2x -9.8x -132.7x
EV/EBIT 23.9x -7.6x -91.1x
EV/Revenue 2.5x 27.6x 14.7x
EV/FCF 27.9x -14.1x -498.0x
EV/Operating cash flow 19.8x -14.4x -1,027x
PEG (3Y EPS CAGR) 1.72 – -1.90

Growth

14 metrics
MetricLHGRALADPT
Revenue growth (1Y) 6.0% 12.3% 17.9%
Revenue CAGR (3Y) 6.6% – 18.4%
Gross profit growth (1Y) 8.0% 13.1% 21.7%
Gross profit CAGR (3Y) 8.2% – 27.3%
Operating income growth (1Y) 12.6% -0.7% 38.3%
Operating income CAGR (3Y) 19.7% – 37.3%
Net income growth (1Y) 17.4% 0.0% 11.1%
Net income CAGR (3Y) 14.9% – 28.8%
EPS growth (1Y) 20.4% 22.8% 22.7%
EPS CAGR (3Y) 17.4% – 34.7%
Operating cash flow growth (1Y) 0.6% 6.8% 92.9%
Operating cash flow CAGR (3Y) 9.0% – 70.1%
Free cash flow growth (1Y) -6.8% 5.4% 86.0%
Free cash flow CAGR (3Y) 8.2% – 62.8%

Profitability

14 metrics
MetricLHGRALADPT
Gross margin 29.0% 47.2% 74.2%
EBITDA margin 15.1% -282.4% -11.1%
Operating margin 10.3% -363.4% -16.2%
Pretax margin 8.4% -344.3% 5.1%
Net margin 6.9% -255.1% -23.7%
FCF margin 8.8% -196.0% -3.0%
Operating cash flow margin 12.4% -192.4% -1.4%
Return on equity 11.5% -16.3% -42.3%
Return on assets 5.4% -14.6% -10.7%
Return on invested capital 8.3% – –
Return on capital employed 9.4% -21.5% -8.6%
Asset turnover 0.8x 0.1x 0.5x
Cash conversion (OCF / net income) 1.8x 0.8x 0.1x
Stock comp / revenue 0.9% 40.3% 15.5%

Financial Health

11 metrics
MetricLHGRALADPT
Debt / assets 31.9% – –
Debt / equity 0.7x – –
Net debt / EBITDA 2.6x – –
Debt / FCF 4.7x – –
Liabilities / assets 53.2% 10.1% 73.1%
Equity / assets 46.8% 89.9% 26.9%
Interest coverage 6.5x – -5.3x
Current ratio 1.4x 8.9x 4.0x
Quick ratio 1.0x 8.6x 3.7x
Cash ratio 0.1x 8.4x 3.0x
Altman Z-score 3.56 5.53 3.45

Shareholder Returns

7 metrics
MetricLHGRALADPT
Dividend yield 0.8% – –
Net buyback yield 2.0% – -0.9%
Shareholder yield 2.7% – -0.9%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusLHGRALADPT
Forward P/E 21.5xFY2026 – –
EPS, next fiscal year $17.22FY2026 $-9.16FY2026 $-0.42FY2026
EPS growth, next FY +4.7%FY2026 – –
EPS growth, the year after +7.8% – –
Revenue, next fiscal year $14.39BFY2026 $158.71MFY2026 $297.43MFY2026
Revenue growth, next FY +3.1%FY2026 +7.8%FY2026 +7.4%FY2026
Revenue growth, the year after +12.5% +37.5% +32.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersLHGRALADPT
Held by institutions 97.0% 85.4% 97.2%
Institutions holding 1,053 374 301
Change in shares held, QoQ +1.6% +8.4% +2.5%
Institutions buying 466 183 160
Institutions selling 393 101 87
Buyers to sellers 1.19 1.81 1.84

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

LHGRALADPT
LH 1.00 0.16 0.29
GRAL 0.16 1.00 0.48
ADPT 0.29 0.48 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, LH, GRAL and ADPT?

Labcorp Holdings (LH) is the largest by market capitalisation: Labcorp Holdings (LH) $30.24B, Grail (GRAL) $4.98B, Adaptive Biotechnologies (ADPT) $4.50B.

Which company is growing faster?

Adaptive Biotechnologies (ADPT) grew revenue fastest over the trailing twelve months: Labcorp Holdings (LH) +6.0%, Grail (GRAL) +12.3%, Adaptive Biotechnologies (ADPT) +17.9%.

Which company is more profitable?

Labcorp Holdings (LH) has the highest net margin (Labcorp Holdings (LH) 6.9%, Grail (GRAL) -255.1%, Adaptive Biotechnologies (ADPT) -23.7%).

Which stock has performed better?

Over the past year Adaptive Biotechnologies (ADPT) returned the most: Labcorp Holdings (LH) +38.3%, Grail (GRAL) +39.3%, Adaptive Biotechnologies (ADPT) +105.4%. Over five years, Labcorp Holdings (LH) compounded fastest (Labcorp Holdings (LH) +7.7%/yr, Adaptive Biotechnologies (ADPT) -2.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Labcorp Holdings (LH) has been the steadiest (Labcorp Holdings (LH) 24.1%, Grail (GRAL) 112.9%, Adaptive Biotechnologies (ADPT) 67.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, LH, GRAL and ADPT?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Labcorp Holdings (LH) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.